Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Sepsis is a life-threatening syndrome resulting from a dysregulated host response to infection. It is the primary cause of death in the intensive care unit, posing a substantial challenge to human health and medical resource allocation. The pathogenesis and pathophysiology of sepsis are complex. During its onset, pro-inflammatory and anti-inflammatory mechanisms engage in intricate interactions, possibly leading to hyperinflammation, immunosuppression, and long-term immune disease. Of all critical outcomes, hyperinflammation is the main cause of early death among patients with sepsis. Therefore, early suppression of hyperinflammation may improve the prognosis of these patients. Nafamostat mesilate is a serine protease inhibitor, which can inhibit the activation of the complement system, coagulation system, and contact system. In this review, we discuss the pathophysiological changes occurring in these systems during sepsis, and describe the possible targets of the serine protease inhibitor nafamostat mesilate in the treatment of this condition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411436 | PMC |
| http://dx.doi.org/10.1016/j.jointm.2024.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Difference in the inhibitory mechanism against TMPRSS2 between camostat and nafamostat: implications for drug design.
Phys Chem Chem Phys
August 2025
Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu 610106, China.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), first identified in late 2019 as the causative agent of the COVID-19 pandemic, has triggered a global public health crisis. Transmembrane protease serine 2 (TMPRSS2) is one of the key host factors mediating SARS-CoV-2 infection and invasion. The inhibitors against TMPRSS2 emerge as a promising therapeutic strategy for COVID-19 and other potential viral infections.
View Article and Find Full Text PDFDifferent anticoagulation methods for continuous renal replacement therapy in patients with hyperlactataemia and a high risk of bleeding.
Int J Artif Organs
August 2025
Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Background: There is a lack of consensus regarding the optimal anticoagulation strategy for continuous renal replacement therapy (CRRT) in patients with hyperlactataemia and a high risk of bleeding. The purpose of this study was to evaluate the safety and efficacy of the commonly used anticoagulation methods for CRRT in these patients.
Methods: The present study included patients with hyperlactataemia (⩾2 mmol/L) and a high risk of bleeding who underwent CRRT at Xijing Hospital from 2020 to 2024.
Mechanisms of histopathologic vascular damage caused by pancreatic juice leakage: Implications for preventing hemorrhagic complications.
Surgery
August 2025
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address:
Background: This study presents a prospective experimental analysis aimed to investigate the enzymatic interactions that cause histologic changes in the vascular wall to help prevent bleeding complications after pancreatic surgery. Severe hemorrhage can result from the accumulation of pancreatic juice and digestive fluids around vascular stumps. However, the specific digestive enzymes and their interactions that cause histologic damage to vascular walls remain unclear.
View Article and Find Full Text PDFEfficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial.
Trials
July 2025
Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.
Background: Sepsis is the leading cause of death in critically ill patients, with an in-hospital mortality rate of approximately 25% to 40%. Coagulation activation serves as an initial factor to the progression of sepsis into multiple organ dysfunction syndrome (MODS). Therefore, anticoagulant therapy may be beneficial.
View Article and Find Full Text PDFSynergistic activation of bat SARS-like coronaviruses spike protein by elastase and TMPRSS2.
Sci Rep
July 2025
Laboratory of Molecular Targeted Therapy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1, Niijuku, Katsushika-ku, Tokyo, 125-8585, Japan.
Although numerous sarbecoviruses have been identified in bats, but most lack the ability to infect human cells. Some barriers limit coronavirus zoonosis, including susceptibility to host proteases. Here, we investigated whether exogenous protease treatment can circumvent host restrictions in two severe acute respiratory syndrome (SARS)-related bat coronaviruses.
View Article and Find Full Text PDF